NCT00276770

Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas

NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy Using [F18] Fluorothymidine (FLT) As a Marker of Proliferation in Patients With Primary Brain Tumors

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University of Washington · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Diagnostic procedures, such as positron emission tomography using fluorothymidine F 18, may be effective in finding recurrent disease in patients with gliomas. PURPOSE: This clinical trial is studying how well positron emission tomography using fluorothymidine F 18 works in finding recurrent disease in patients with gliomas.

Detailed description

OBJECTIVES: Primary * Determine the safety of fluorothymidine F 18 for visual and dynamic brain tumor images in patients with glial neoplasms. * Determine, preliminarily, the efficacy of this drug. Secondary * Compare, preliminarily, the efficacy of this drug to fludeoxyglucose F 18 in differentiating tumor recurrence from radiation necrosis. * Determine the optimal time to image post injection of this drug. OUTLINE: This is a pilot, nonrandomized study. Patients receive fluorothymidine F 18 IV over 1 minute and then undergo positron emission tomography (PET) scanning of the brain over 2 hours. After completion of the PET scan, patients are followed for at least 1 month. PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.

Conditions

• Brain and Central Nervous System Tumors

Interventions

Type	Name	Description
OTHER	fluorine F 18 fluorothymidine
PROCEDURE	positron emission tomography

Timeline

• Start date: 2006-02-01
• Primary completion: 2007-05-01
• First posted: 2006-01-13
• Last updated: 2019-02-27

Locations

1 site across 1 country: United States